MHB042C for people with advanced solid tumors

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This first-in-human, open-label Phase 1/2 trial gives MHB042C by injection to adults with advanced solid tumors and includes a dose-escalation stage followed by dose-expansion cohorts. The dose-escalation phase will determine safety, tolerability, pharmacokinetics, and the maximum tolerated dose, with a PK expansion at selected dose levels. The dose-expansion phase will enroll multiple tumor-specific cohorts to further characterize safety and preliminary antitumor activity. Key endpoints include dose-limiting toxicities, adverse events, pharmacokinetic profiles, and objective tumor responses per RECIST v1.1.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Voluntarily agrees to participate in the study and signs the informed consent form.
2. Age ≥ 18 years, no restriction on gender.
3. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.
4. Estimated life expectancy ≥ 3 months.
5. Histologically or cytologically confirmed advanced solid tumors that are refractory to standard therapy, intolerant to standard therapy, or have no standard treatment options.
6. At least one measurable lesion per RECIST v1.1 criteria or one bone.
7. Adequate bone marrow reserve and organ function. -

Exclusion Criteria:

1. History of ≥2 primary malignancies within 5 years prior to informed consent.
2. Received chemotherapy within 3 weeks, radiotherapy within 4 weeks, or biologic, endocrine, or immunotherapy within 4 weeks before first study dose.
3. Medication of other unmarketed investigational drugs or therapies within 4 weeks before the first dose of investigational drug.
4. Brain metastases, bone marrow metastases, leptomeningeal disease, brainstem metastases, or spinal cord compression.
5. Severe bone damage caused by bone metastasis of prostate cancer.
6. Has adverse reactions from previous anti-tumor treatment that have not recovered to ≤ CTCAE 5.0 Grade 1.
7. Severe lung disease affecting pulmonary function.
8. Vaccinated within 4 weeks before dosing.
9. Active systemic infection requiring treatment within 7 days before dosing.
10. Serious cardiovascular or cerebrovascular diseases.
11. Uncontrolled third-space effusions not suitable for enrollment.
12. Significant bleeding, bleeding tendency, or non-healing wounds within 1 month before first dose.
13. Known hypersensitivity or delayed allergic reaction to the investigational product or its components.
14. Drug abuse or other medical/psychiatric condition that may interfere with study participation or results.
15. Known alcohol or drug dependence.
16. Pregnant or breastfeeding women, or individuals planning to conceive. -

Where it's running

• Guangdong Provincial People's Hospital
  Guangzhou, Guangdong, China Recruiting

Study contacts

• Study coordinator: CMO/ Senior Vice President of R&D
• Email: jwshi@minghuipharma.com
• Phone: +86 0571-86963293

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Three-dimensional lattice radiotherapy with PD-1/PD-L1 inhibitors for advanced solid tumors

  This study tests whether adding lattice radiotherapy to PD-1/PD-L1 inhibitors is safe and helps people with advanced solid tumors that have grown or spread.

  Recruiting Phase 2 Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Shenzhen, Guangdong · NCT07865793

• YH02 injection for intratumor therapy in advanced solid tumors

  This phase 2 study tests YH02 injected directly into tumors to see if it can help people with advanced solid cancers who have no effective standard treatments left.

  Recruiting Phase 2 Tianjin First Central Hospital · Tianjin · NCT07697937

• VG2025: a targeted therapy for advanced solid tumors

  This trial tests VG2025, an oncolytic HSV-1 therapy, in adults with advanced solid tumors that have stopped responding to standard treatments to see if it is safe and tolerable and to find a potential starting dose for future studies.

  Recruiting Phase 1/2 Virogin Biotech Ltd. · Shanghai · NCT07682870

• Immunotherapy with NY-ESO-1 TCR dnTGFβRII cells for ovarian cancer and other advanced solid tumors

  This trial tests a gene-modified T cell therapy, given with or without decitabine, in adults whose tumors express NY-ESO-1.

  Recruiting Phase 1/2 University of Chicago · Chicago, Illinois · NCT07389239

• First-in-human use of PLT012 in adults with advanced solid tumors

  This study will try different doses of an experimental drug called PLT012 given by IV every three weeks in adults with advanced solid tumors to find safe doses and see if it shrinks tumors.

  Recruiting at 4 sites Phase 1 Pilatus Biosciences Inc · Los Angeles, California and 3 other locations · NCT07337525

• MHB009C for adults with advanced solid tumors

  This trial will try MHB009C, an experimental injectable drug, in adults with advanced solid tumors who have no standard treatment options.

  Recruiting Phase 1/2 Minghui Pharmaceutical (Hangzhou) Ltd · Shanghai, Shanghai Municipality · NCT07326488

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.